Distal cholangiocarcinoma

Surgical Clinics of North America

Volumn 94, Issue 2, 2014, Pages 325-342

  Dickson, Paxton V ^a   Behrman, Stephen W ^a  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

Adjuvant therapy; Cholangiocarcinoma; Pathophysiology; Surgery

Indexed keywords

ANTINEOPLASTIC AGENT; CA 19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; CISPLATIN; CYCLOOXYGENASE 2; EPIDERMAL GROWTH FACTOR RECEPTOR; FLUOROPYRIMIDINE; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; INTERLEUKIN 6; MICRORNA; MITOMYCIN; PROGRANULIN; PROTEIN P53; VASCULOTROPIN;

BILE DUCT; BILE DUCT CARCINOMA; CANCER ADJUVANT THERAPY; CANCER INCIDENCE; CANCER PALLIATIVE THERAPY; CANCER PROGNOSIS; CANCER RISK; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CHEMORADIOTHERAPY; CHOLESTASIS; CLINICAL FEATURE; COMMON BILE DUCT CYST; DISTAL CHOLANGIOCARCINOMA; DISTANT METASTASIS; GENE MUTATION; HUMAN; JAUNDICE; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; PANCREATICODUODENECTOMY; PARASITOSIS; PORTAL VEIN; PRIMARY SCLEROSING CHOLANGITIS; PRIORITY JOURNAL; PRURITUS; REVIEW;

ADJUVANT THERAPY; CHOLANGIOCARCINOMA; PATHOPHYSIOLOGY; SURGERY;

BILE DUCT NEOPLASMS; BILE DUCTS, INTRAHEPATIC; CHEMOTHERAPY, ADJUVANT; CHOLANGIOCARCINOMA; CHOLANGITIS, SCLEROSING; CHOLEDOCHAL CYST; EARLY DETECTION OF CANCER; GENES, P53; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; LIVER DISEASES, PARASITIC; MUTATION; PALLIATIVE CARE; PRECANCEROUS CONDITIONS; RADIOTHERAPY, ADJUVANT; RISK FACTORS;

EID: 84896947386     PISSN: 00396109     EISSN: 15583171     Source Type: Journal    
DOI: 10.1016/j.suc.2013.12.004     Document Type: Review

References (75)

1. Welzel T.M., McGlynn K.A., Hsing A.W., et al. Impact of classification of hilar cholangiocarcinomas (Klatskin tumors) on the incidence of intra- and extrahepatic cholangiocarcinoma in the United States. JNatl Cancer Inst 2006, 98(12):873-875.
2. Cardinale V., Semeraro R., Torrice A., et al. Intra-hepatic and extra-hepatic cholangiocarcinoma: new insight into epidemiology and risk factors. World J Gastrointest Oncol 2010, 2(11):407-416.
3. Shaib Y., El-Serag H.B. The epidemiology of cholangiocarcinoma. Semin Liver Dis 2004, 24(2):115-125.
4. Tyson G.L., El-Serag H.B. Risk factors for cholangiocarcinoma. Hepatology 2011, 54(1):173-184.
5. Jing W., Jin G., Zhou X., et al. Diabetes mellitus and increased risk of cholangiocarcinoma: a meta-analysis. Eur J Cancer Prev 2012, 21(1):24-31.
6. Claessen M.M., Vleggaar F.P., Tytgat K.M., et al. High lifetime risk of cancer in primary sclerosing cholangitis. JHepatol 2009, 50(1):158-164.
7. Bjornsson E., Lindqvist-Ottosson J., Asztely M., et al. Dominant strictures in patients with primary sclerosing cholangitis. Am J Gastroenterol 2004, 99(3):502-508.
8. Abraham S.C., Wilentz R.E., Yeo C.J., et al. Pancreaticoduodenectomy (Whipple resections) in patients without malignancy: are they all 'chronic pancreatitis'?. Am J Surg Pathol 2003, 27(1):110-120.
9. Sutcliffe R.P., Lam W., O'Sullivan A., et al. Pancreaticoduodenectomy after liver transplantation in patients with primary sclerosing cholangitis complicated by distal pancreatobiliary malignancy. World J Surg 2010, 34(9):2128-2132.
10. Landaverde C., Ng V., Sato A., et al. De-novo cholangiocarcinoma in native common bile duct remnant following OLT for primary sclerosing cholangitis. Ann Hepatol 2009, 8(4):379-383.
11. Aljiffry M., Renfrew P.D., Walsh M.J., et al. Analytical review of diagnosis and treatment strategies for dominant bile duct strictures in patients with primary sclerosing cholangitis. HPB (Oxford) 2011, 13(2):79-90.
12. Soreide K., Korner H., Havnen J., et al. Bile duct cysts in adults. Br J Surg 2004, 91(12):1538-1548.
13. Dong J.H., Yang S.Z., Xia H.T., et al. Aggressive hepatectomy for the curative treatment of bilobar involvement of type IV-A bile duct cyst. Ann Surg 2013, 258(1):122-128.
14. Kaewpitoon N., Kaewpitoon S.J., Pengsaa P., et al. Opisthorchis viverrini: the carcinogenic human liver fluke. World J Gastroenterol 2008, 14(5):666-674.
15. Parkin D.M., Srivatanakul P., Khlat M., et al. Liver cancer in Thailand. I. A case-control study of cholangiocarcinoma. Int J Cancer 1991, 48(3):323-328.
16. Honjo S., Srivatanakul P., Sriplung H., et al. Genetic and environmental determinants of risk for cholangiocarcinoma via Opisthorchis viverrini in a densely infested area in Nakhon Phanom, northeast Thailand. Int J Cancer 2005, 117(5):854-860.
17. Shin H.R., Lee C.U., Park H.J., et al. Hepatitis B and C virus, Clonorchis sinensis for the risk of liver cancer: a case-control study in Pusan, Korea. Int J Epidemiol 1996, 25(5):933-940.
18. Yoon H.A., Noh M.H., Kim B.G., et al. Clinicopathological significance of altered Notch signaling in extrahepatic cholangiocarcinoma and gallbladder carcinoma. World J Gastroenterol 2011, 17(35):4023-4030.
19. Werneburg N.W., Yoon J.H., Higuchi H., et al. Bile acids activate EGF receptor via a TGF-alpha-dependent mechanism in human cholangiocyte cell lines. Am J Physiol Gastrointest Liver Physiol 2003, 285(1):G31-G36.
20. Isomoto H., Kobayashi S., Werneburg N.W., et al. Interleukin 6 upregulates myeloid cell leukemia-1 expression through a STAT3 pathway in cholangiocarcinoma cells. Hepatology 2005, 42(6):1329-1338.
21. Kobayashi S., Werneburg N.W., Bronk S.F., et al. Interleukin-6 contributes to Mcl-1 up-regulation and TRAIL resistance via an Akt-signaling pathway in cholangiocarcinoma cells. Gastroenterology 2005, 128(7):2054-2065.
22. Frampton G., Invernizzi P., Bernuzzi F., et al. Interleukin-6-driven progranulin expression increases cholangiocarcinoma growth by an Akt-dependent mechanism. Gut 2012, 61(2):268-277.
23. Yoon J.H., Canbay A.E., Werneburg N.W., et al. Oxysterols induce cyclooxygenase-2 expression in cholangiocytes: implications for biliary tract carcinogenesis. Hepatology 2004, 39(3):732-738.
24. Ogasawara S., Yano H., Higaki K., et al. Expression of angiogenic factors, basic fibroblast growth factor and vascular endothelial growth factor, in human biliary tract carcinoma cell lines. Hepatol Res 2001, 20(1):97-113.
25. Nonomura A., Ohta G., Nakanuma Y., et al. Simultaneous detection of epidermal growth factor receptor (EGF-R), epidermal growth factor (EGF) and ras p21 in cholangiocarcinoma by an immunocytochemical method. Liver 1988, 8(3):157-166.
26. Arumugam T., Ramachandran V., Fournier K.F., et al. Epithelial to mesenchymal transition contributes to drug resistance in pancreatic cancer. Cancer Res 2009, 69(14):5820-5828.
27. Yao X., Wang X., Wang Z., et al. Clinicopathological and prognostic significance of epithelial mesenchymal transition-related protein expression in intrahepatic cholangiocarcinoma. Onco Targets Ther 2012, 5:255-261.
28. Itatsu K., Sasaki M., Yamaguchi J., et al. Cyclooxygenase-2 is involved in the up-regulation of matrix metalloproteinase-9 in cholangiocarcinoma induced by tumor necrosis factor-alpha. Am J Pathol 2009, 174(3):829-841.
29. Nault J.C., Zucman-Rossi J. Genetics of hepatobiliary carcinogenesis. Semin Liver Dis 2011, 31(2):173-187.
30. Voss J.S., Holtegaard L.M., Kerr S.E., et al. Molecular profiling of cholangiocarcinoma shows potential for targeted therapy treatment decisions. Hum Pathol 2013, 44(7):1216-1222.
31. Papaconstantinou I., Karakatsanis A., Gazouli M., et al. The role of microRNAs in liver cancer. Eur J Gastroenterol Hepatol 2012, 24(3):223-228.
32. Corazziari E. Biliary tract imaging. Curr Gastroenterol Rep 1999, 1(2):123-131.
33. Sharma M.P., Ahuja V. Aetiological spectrum of obstructive jaundice and diagnostic ability of ultrasonography: a clinician's perspective. Trop Gastroenterol 1999, 20(4):167-169.
34. Slattery J.M., Sahani D.V. What is the current state-of-the-art imaging for detection and staging of cholangiocarcinoma?. Oncologist 2006, 11(8):913-922.
35. Benson AB 3rd, Abrams TA, Ben-Josef E, et al. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®). Hepatobiliary Cancers. Version 1.2014. © 2014 National Comprehensive Cancer Network, Inc. Available at:. Accessed February 27, 2014. http://NCCN.org.
36. Kubota Y., Takaoka M., Tani K., et al. Endoscopic transpapillary biopsy for diagnosis of patients with pancreaticobiliary ductal strictures. Am J Gastroenterol 1993, 88(10):1700-1704.
37. Ponchon T., Gagnon P., Berger F., et al. Value of endobiliary brush cytology and biopsies for the diagnosis of malignant bile duct stenosis: results of a prospective study. Gastrointest Endosc 1995, 42(6):565-572.
38. Sugiyama M., Atomi Y., Wada N., et al. Endoscopic transpapillary bile duct biopsy without sphincterotomy for diagnosing biliary strictures: a prospective comparative study with bile and brush cytology. Am J Gastroenterol 1996, 91(3):465-467.
39. Wu L.M., Jiang X.X., Gu H.Y., et al. Endoscopic ultrasound-guided fine-needle aspiration biopsy in the evaluation of bile duct strictures and gallbladder masses: a systematic review and meta-analysis. Eur J Gastroenterol Hepatol 2011, 23(2):113-120.
40. Gabbert C., Warndorf M., Easler J., et al. Advanced techniques for endoscopic biliary imaging: cholangioscopy, endoscopic ultrasonography, confocal, and beyond. Gastrointest Endosc Clin N Am 2013, 23(3):625-646.
41. Osanai M., Itoi T., Igarashi Y., et al. Peroral video cholangioscopy to evaluate indeterminate bile duct lesions and preoperative mucosal cancerous extension: a prospective multicenter study. Endoscopy 2013, 45(8):635-642.
42. Malaguarnera G., Paladina I., Giordano M., et al. Serum markers of intrahepatic cholangiocarcinoma. Dis Markers 2013, 34(4):219-228.
43. Alvaro D. Serum and bile biomarkers for cholangiocarcinoma. Curr Opin Gastroenterol 2009, 25(3):279-284.
44. Jesudian A.B., Jacobson I.M. Screening and diagnosis of cholangiocarcinoma in patients with primary sclerosing cholangitis. Rev Gastroenterol Disord 2009, 9(2):E41-E47.
45. Konishi M., Iwasaki M., Ochiai A., et al. Clinical impact of intraoperative histological examination of the ductal resection margin in extrahepatic cholangiocarcinoma. Br J Surg 2010, 97(9):1363-1368.
46. Yeo T.P., Hruban R.H., Leach S.D., et al. Pancreatic cancer. Curr Probl Cancer 2002, 26(4):176-275.
47. Nakeeb A., Lillemoe K.D., Grosfeld J.L. Surgical techniques for pancreatic cancer. Minerva Chir 2004, 59(2):151-163.
48. Riediger H., Makowiec F., Fischer E., et al. Postoperative morbidity and long-term survival after pancreaticoduodenectomy with superior mesenterico-portal vein resection. JGastrointest Surg 2006, 10(8):1106-1115.
49. Harrison L.E., Klimstra D.S., Brennan M.F. Isolated portal vein involvement in pancreatic adenocarcinoma. A contraindication for resection?. Ann Surg 1996, 224(3):342-347. [discussion: 347-9].
50. Tseng J.F., Raut C.P., Lee J.E., et al. Pancreaticoduodenectomy with vascular resection: margin status and survival duration. JGastrointest Surg 2004, 8(8):935-949. [discussion: 949-50].
51. Stitzenberg K.B., Watson J.C., Roberts A., et al. Survival after pancreatectomy with major arterial resection and reconstruction. Ann Surg Oncol 2008, 15(5):1399-1406.
52. Chua T.C., Saxena A. Extended pancreaticoduodenectomy with vascular resection for pancreatic cancer: a systematic review. JGastrointest Surg 2010, 14(9):1442-1452.
53. LaFemina J., Chou J.F., Gonen M., et al. Hepatic arterial nodal metastases in pancreatic cancer: is this the node of importance?. JGastrointest Surg 2013, 17(6):1092-1097.
54. Tempero MA, Arnoletti JP, Behrman SW, et al. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®). Pancreatic Adenocarcinoma. Version 1.2014. © 2013 National Comprehensive Cancer Network, Inc. Available at:. Accessed February 27, 2014. http://NCCN.org.
55. Verbeke C.S. Resection margins in pancreatic cancer. Surg Clin North Am 2013, 93(3):647-662.
56. Verbeke C.S. Resection margins and R1 rates in pancreatic cancer: are we there yet?. Histopathology 2008, 52(7):787-796.
57. WashingtonK, etal. Protocol for the Examination of Specimens From Patients With Carcinoma of the Exocrine Pancreas. College of American Pathologists (CAP). Available at:. Accessed February 28, 2014. http://cap.org.
58. Mitsunaga S., Hasebe T., Iwasaki M., et al. Important prognostic histological parameters for patients with invasive ductal carcinoma of the pancreas. Cancer Sci 2005, 96(12):858-865.
59. Gebhardt C., Meyer W., Reichel M., et al. Prognostic factors in the operative treatment of ductal pancreatic carcinoma. Langenbecks Arch Surg 2000, 385(1):14-20.
60. Distal bile duct. AJCC cancer staging manual 2010, 227-233. Springer, New York. 7th edition. S.B. Edge, D.R. Byrd (Eds.).
61. DeOliveira M.L., Cunningham S.C., Cameron J.L., et al. Cholangiocarcinoma: thirty-one-year experience with 564 patients at a single institution. Ann Surg 2007, 245(5):755-762.
62. Murakami Y., Uemura K., Sudo T., et al. Prognostic factors after surgical resection for intrahepatic, hilar, and distal cholangiocarcinoma. Ann Surg Oncol 2011, 18(3):651-658.
63. Murakami Y., Uemura K., Hayashidani Y., et al. Prognostic significance of lymph node metastasis and surgical margin status for distal cholangiocarcinoma. JSurg Oncol 2007, 95(3):207-212.
64. He P., Shi J.S., Chen W.K., et al. Multivariate statistical analysis of clinicopathologic factors influencing survival of patients with bile duct carcinoma. World J Gastroenterol 2002, 8(5):943-946.
65. Hong S.M., Pawlik T.M., Cho H., et al. Depth of tumor invasion better predicts prognosis than the current American Joint Committee on Cancer T classification for distal bile duct carcinoma. Surgery 2009, 146(2):250-257.
66. Takada T., Amano H., Yasuda H., et al. Is postoperative adjuvant chemotherapy useful for gallbladder carcinoma? A phase III multicenter prospective randomized controlled trial in patients with resected pancreaticobiliary carcinoma. Cancer 2002, 95(8):1685-1695.
67. Neoptolemos J.P., Stocken D.D., Bassi C., et al. Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial. JAMA 2010, 304(10):1073-1081.
68. Hughes M.A., Frassica D.A., Yeo C.J., et al. Adjuvant concurrent chemoradiation for adenocarcinoma of the distal common bile duct. Int J Radiat Oncol Biol Phys 2007, 68(1):178-182.
69. Yeo C.J., Sohn T.A., Cameron J.L., et al. Periampullary adenocarcinoma: analysis of 5-year survivors. Ann Surg 1998, 227(6):821-831.
70. Nelson J.W., Ghafoori A.P., Willett C.G., et al. Concurrent chemoradiotherapy in resected extrahepatic cholangiocarcinoma. Int J Radiat Oncol Biol Phys 2009, 73(1):148-153.
71. Borghero Y., Crane C.H., Szklaruk J., et al. Extrahepatic bile duct adenocarcinoma: patients at high-risk for local recurrence treated with surgery and adjuvant chemoradiation have an equivalent overall survival to patients with standard-risk treated with surgery alone. Ann Surg Oncol 2008, 15(11):3147-3156.
72. Lim K.H., Oh D.Y., Chie E.K., et al. Adjuvant concurrent chemoradiation therapy (CCRT) alone versus CCRT followed by adjuvant chemotherapy: which is better in patients with radically resected extrahepatic biliary tract cancer? A non-randomized, single center study. BMC Cancer 2009, 9:345.
73. Hezel A.F., Zhu A.X. Systemic therapy for biliary tract cancers. Oncologist 2008, 13(4):415-423.
74. Eckel F., Schmid R.M. Chemotherapy in advanced biliary tract carcinoma: a pooled analysis of clinical trials. Br J Cancer 2007, 96(6):896-902.
75. Valle J., Wasan H., Palmer D.H., et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. NEngl J Med 2010, 362(14):1273-1281.